A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the combination of bevacizumab and
bortezomib have increased efficacy in the treatment of relapsed/ refractory multiple myeloma.
Phase:
Phase 2
Details
Lead Sponsor:
Hackensack Meridian Health Hackensack University Medical Center